William E Delaney

Summary

Affiliation: Gilead Sciences
Country: USA

Publications

  1. ncbi request reprint Progress in the treatment of chronic hepatitis B: long-term experience with adefovir dipivoxil
    William E Delaney
    Gilead Sciences Inc, 333 Lakeside Dr, Foster City, CA 94404, USA
    J Antimicrob Chemother 59:827-32. 2007
  2. ncbi request reprint Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation
    W E Delaney
    Victorian Infectious Diseases Reference Laboratory, North Melbourne, Australia
    Antivir Chem Chemother 12:1-35. 2001
  3. pmc Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro
    William E Delaney
    Gilead Sciences, Inc, Foster City, CA 94402, USA
    Antimicrob Agents Chemother 48:3702-10. 2004
  4. pmc The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro
    William E Delaney
    Gilead Sciences Inc, Foster City, California 94404, USA
    J Virol 77:11833-41. 2003
  5. doi request reprint Discovery of GS-9256: a novel phosphinic acid derived inhibitor of the hepatitis C virus NS3/4A protease with potent clinical activity
    X Christopher Sheng
    Gilead Sciences, Inc, 333 Lakeside Dr, Foster City, CA 94404, USA
    Bioorg Med Chem Lett 22:1394-6. 2012
  6. ncbi request reprint In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents
    Xiaoping Qi
    Department of Clinical Virology, Gilead Sciences, Foster City, CA, USA
    Antivir Ther 12:355-62. 2007
  7. ncbi request reprint Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B
    Christopher E Westland
    Gilead Sciences, Inc, Foster City, CA
    Hepatology 38:96-103. 2003
  8. ncbi request reprint Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro
    Robert Y m Chen
    Victorian Infectious Diseases Reference Laboratory, North Melbourne, Victoria, Australia
    Hepatology 37:27-35. 2003
  9. doi request reprint Discovery of GS-9451: an acid inhibitor of the hepatitis C virus NS3/4A protease
    X Christopher Sheng
    Gilead Sciences, Inc, 333 Lakeside Dr, Foster City, CA 94404, USA
    Bioorg Med Chem Lett 22:2629-34. 2012
  10. ncbi request reprint Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks
    Huiling Yang
    Gilead Sciences Inc, Foster City, CA 94404, USA
    Hepatology 36:464-73. 2002

Collaborators

Detail Information

Publications34

  1. ncbi request reprint Progress in the treatment of chronic hepatitis B: long-term experience with adefovir dipivoxil
    William E Delaney
    Gilead Sciences Inc, 333 Lakeside Dr, Foster City, CA 94404, USA
    J Antimicrob Chemother 59:827-32. 2007
    ..The efficacy of adefovir dipivoxil in treating lamivudine-resistant HBV and the delayed emergence of adefovir resistance are key factors contributing to the durable response achieved in broad groups of chronic hepatitis B patients...
  2. ncbi request reprint Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation
    W E Delaney
    Victorian Infectious Diseases Reference Laboratory, North Melbourne, Australia
    Antivir Chem Chemother 12:1-35. 2001
    ..Here we review the basis of drug resistance in HBV, with emphasis on aspects that are likely to affect drug choice in future...
  3. pmc Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro
    William E Delaney
    Gilead Sciences, Inc, Foster City, CA 94402, USA
    Antimicrob Agents Chemother 48:3702-10. 2004
    ..There was no evidence of cytotoxicity with any of the drugs when used alone or in combination at the tested doses...
  4. pmc The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro
    William E Delaney
    Gilead Sciences Inc, Foster City, California 94404, USA
    J Virol 77:11833-41. 2003
    ..Together, these results suggest that rtV173L is a compensatory mutation that is selected in lamivudine-resistant patients due to an enhanced replication phenotype...
  5. doi request reprint Discovery of GS-9256: a novel phosphinic acid derived inhibitor of the hepatitis C virus NS3/4A protease with potent clinical activity
    X Christopher Sheng
    Gilead Sciences, Inc, 333 Lakeside Dr, Foster City, CA 94404, USA
    Bioorg Med Chem Lett 22:1394-6. 2012
    ..Based on these attributes, GS-9256 was advanced to human clinical trial as a treatment for chronic infection with genotype 1 HCV...
  6. ncbi request reprint In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents
    Xiaoping Qi
    Department of Clinical Virology, Gilead Sciences, Foster City, CA, USA
    Antivir Ther 12:355-62. 2007
    ..The rtA181T mutation has also been observed at low frequency, alone or in combination with rtN236T...
  7. ncbi request reprint Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B
    Christopher E Westland
    Gilead Sciences, Inc, Foster City, CA
    Hepatology 38:96-103. 2003
    ..In conclusion, no adefovir resistance mutations were identified in a large group of chronic hepatitis B patients treated with ADV for 48 weeks...
  8. ncbi request reprint Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro
    Robert Y m Chen
    Victorian Infectious Diseases Reference Laboratory, North Melbourne, Victoria, Australia
    Hepatology 37:27-35. 2003
    ..In conclusion, the PC stop codon mutation appears to increase the replication efficacy of lamivudine-resistant virus but does not affect in vitro drug sensitivity...
  9. doi request reprint Discovery of GS-9451: an acid inhibitor of the hepatitis C virus NS3/4A protease
    X Christopher Sheng
    Gilead Sciences, Inc, 333 Lakeside Dr, Foster City, CA 94404, USA
    Bioorg Med Chem Lett 22:2629-34. 2012
    ..Modification of the P3 cap and P2 quinoline with a series of solubilizing groups led to the identification of potent HCV NS3 protease inhibitors with greatly improved pharmacokinetic properties in rats, dogs and monkeys...
  10. ncbi request reprint Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks
    Huiling Yang
    Gilead Sciences Inc, Foster City, CA 94404, USA
    Hepatology 36:464-73. 2002
    ..In conclusion, these results, although based on a limited number of patients, suggest that treatment with ADV does not lead to the emergence of resistant virus after up to 60 weeks of therapy...
  11. ncbi request reprint In vitro antiviral susceptibility of full-length clinical hepatitis B virus isolates cloned with a novel expression vector
    Huiling Yang
    Gilead Sciences, 333 Lakeside Drive, Foster City, CA 94404, USA
    Antiviral Res 61:27-36. 2004
    ..The vector described here enables the efficient phenotypic analysis of full-length HBV isolates from patients and will be useful in future studies including resistance surveillance, cross-resistance analyses, and novel drug-discovery...
  12. doi request reprint Screening of hepatitis C virus inhibitors using genotype 1a HCV replicon cell lines
    Margaret Robinson
    Gilead Sciences, Foster City, California, USA
    Curr Protoc Microbiol . 2011
    ..Specific protocols are provided for screening 1a replicons that encode the Renilla luciferase gene and for replicons that do not encode exogenous reporter genes, both in 96-well (manual) and in 384-well (high-throughput) formats...
  13. pmc Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus
    William E Delaney
    Gilead Sciences Inc, 333 Lakeside Drive, Foster City, CA 94404, USA
    Antimicrob Agents Chemother 50:2471-7. 2006
    ..Overall, the antiviral and metabolic profile of tenofovir supports its development for the treatment of chronic hepatitis B...
  14. ncbi request reprint Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV
    Huiling Yang
    Department of Clinical Virology, Gilead Sciences, 333 Lakeside Dr, Foster City, CA, USA
    Antivir Ther 10:625-33. 2005
    ....
  15. doi request reprint An adaptive mutation in NS2 is essential for efficient production of infectious 1b/2a chimeric hepatitis C virus in cell culture
    Katie Chan
    Gilead Sciences, Inc, Foster City, CA 94404, USA
    Virology 422:224-34. 2012
    ..Overall, the efficient production of infectious 1b/2a virus particles will facilitate the discovery and characterization of inhibitors targeting steps that involve the structural genes of genotype 1b HCV...
  16. pmc Novel mutations in a tissue culture-adapted hepatitis C virus strain improve infectious-virus stability and markedly enhance infection kinetics
    Maria V Pokrovskii
    Gilead Sciences, Inc, 333 Lakeside Drive, Foster City, CA 94404
    J Virol 85:3978-85. 2011
    ..This adapted virus will facilitate further studies of the HCV life cycle, virus structure, and high-throughput drug screening...
  17. pmc Novel hepatitis C virus reporter replicon cell lines enable efficient antiviral screening against genotype 1a
    Margaret Robinson
    Gilead Sciences, 333 Lakeside Drive, Foster City, CA 94404, USA
    Antimicrob Agents Chemother 54:3099-106. 2010
    ..These new reagents will enhance drug discovery efforts targeting genotype 1a and facilitate the profiling of compound activity among different HCV genotypes and subtypes...
  18. pmc Cellular growth kinetics distinguish a cyclophilin inhibitor from an HSP90 inhibitor as a selective inhibitor of hepatitis C virus
    Rudolf K F Beran
    Biology Department, Gilead Sciences, Foster City, California, United States of America
    PLoS ONE 7:e30286. 2012
    ..The assays we describe here are useful for discriminating selective antivirals from compounds that indirectly affect virus replication by reducing host cell viability or slowing cell growth...
  19. doi request reprint Novel, potent, and orally bioavailable phosphinic acid inhibitors of the hepatitis C virus NS3 protease
    Michael O Clarke
    Gilead Sciences, Inc, 333 Lakeside Dr, Foster City, CA 94404, USA
    Bioorg Med Chem Lett 21:3568-72. 2011
    ..The syntheses and preliminary biological evaluation of these phosphinic acids is described...
  20. pmc Preexisting drug-resistance mutations reveal unique barriers to resistance for distinct antivirals
    Margaret Robinson
    Gilead Sciences, Foster City, CA 94404, USA
    Proc Natl Acad Sci U S A 108:10290-5. 2011
    ..These insights into RNA virus quasispecies structure provide guidance for selecting clinical drug concentrations and selecting antiviral drug combinations most likely to suppress resistance...
  21. pmc Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro
    William E Delaney
    Victorian Infectious Diseases Reference Laboratory, North Melbourne, Victoria 3051, Australia
    Antimicrob Agents Chemother 46:3057-60. 2002
    ..40 +/- 0.92 micro M, respectively, compared to 0.064 +/- 0.020 micro M lamivudine. There were no significant differences in sensitivity between wild-type and nucleoside analogue-resistant (rtL180M, rtM204I, and rtL180M + rtM204V) HBV...
  22. doi request reprint Comparison of HCV NS3 protease and NS5B polymerase inhibitor activity in 1a, 1b and 2a replicons and 2a infectious virus
    Matthew S Paulson
    Gilead Sciences, Inc, Foster City, CA 94404, USA
    Antiviral Res 83:135-42. 2009
    ..Importantly, we observed a significant correlation (p<0.0001) in antiviral potency between the 2a replicon and 2a infectious virus for all classes of compounds tested...
  23. doi request reprint New therapeutic targets and drugs for the treatment of chronic hepatitis B
    Simon P Fletcher
    Department of Biology, Gilead Sciences, Foster City, California 94404, USA
    Semin Liver Dis 33:130-7. 2013
    ..Thus, functional cure of CHB infection remains an important therapeutic challenge...
  24. doi request reprint Molecular virology of chronic hepatitis B and C: parallels, contrasts and impact on drug development and treatment outcome
    William E Delaney
    Gilead Sciences, 333 Lakeside Drive, Foster City, CA 94404, USA
    Antiviral Res 99:34-48. 2013
    ....
  25. doi request reprint A small-molecule inhibitor of hepatitis C virus infectivity
    Caroline O Bush
    Gilead Sciences, Inc, Foster City, California, USA
    Antimicrob Agents Chemother 58:386-96. 2014
    ..Importantly, the discovery of HCV II-1 opens up a new class of HCV inhibitors that prolong viral suppression by HCV replication inhibitors in persistently infected cell cultures. ..
  26. pmc Hepatitis C viral entry inhibitors prolong viral suppression by replication inhibitors in persistently-infected Huh7 cultures
    Caroline O Bush
    Gilead Sciences, Inc, Biology Department, Foster City, California, United States of America
    PLoS ONE 8:e65273. 2013
    ..Our results demonstrated that HCV entry inhibitors combined with replication inhibitors can prolong antiviral suppression, likely due to the delay of viral resistance emergence...
  27. doi request reprint Biochemical evaluation of HCV NS3 protease inhibitors
    Brian Schultz
    Gilead Sciences, Foster City, CA, USA
    Curr Protoc Pharmacol . 2011
    ..The final protocol describes how to determine the reversibility of inhibitor binding to the enzyme, an important parameter that can affect the pharmacodynamic properties of a compound...
  28. doi request reprint Discovery of novel phosphonate derivatives as hepatitis C virus NS3 protease inhibitors
    X Christopher Sheng
    Gilead Sciences, Inc, 333 Lakeside Drive, Foster City, CA 94404, USA
    Bioorg Med Chem Lett 19:3453-7. 2009
    ..The syntheses and preliminary biological evaluation of this phosphonate class of inhibitor are described...
  29. doi request reprint Therapy of chronic hepatitis B: trends and developments
    William E Delaney
    Gilead Sciences, 333 Lakeside Dr Foster City, CA 94404, USA
    Curr Opin Pharmacol 8:532-40. 2008
    ..The challenge is how to best use these drugs long-term to minimize antiviral resistance and maintain maximal antiviral suppression, which is anticipated to make the greatest impact on limiting advanced complications of CHB...
  30. pmc Antiviral effect of oral administration of tenofovir disoproxil fumarate in woodchucks with chronic woodchuck hepatitis virus infection
    Stephan Menne
    Gastrointestinal Unit, Department of Clinical Sciences, College of Veterinary Medicine, Room C 2005 VMC, Cornell University, Ithaca, New York 14853, USA
    Antimicrob Agents Chemother 49:2720-8. 2005
    ..Following drug withdrawal there was prompt recrudescence of WHV viremia to pretreatment levels. It was concluded that oral administration of TDF for 4 weeks was safe and effective in the woodchuck model of chronic HBV infection...
  31. ncbi request reprint Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy
    Bettina Werle-Lapostolle
    INSERM Unit 271, 151 Cours Albert Thomas, 69003 Lyon, France
    Gastroenterology 126:1750-8. 2004
    ..The aim of this study was to develop a sensitive and specific assay for quantifying cccDNA in biopsy samples from chronic hepatitis B patients during different natural history phases and in patients undergoing antiviral therapy...
  32. ncbi request reprint Inhibitory effect of adefovir and lamivudine on the initiation of hepatitis B virus infection in primary tupaia hepatocytes
    Josef Kock
    Department of Medicine II, University of Freiburg, Freiburg, Germany
    Hepatology 38:1410-8. 2003
    ..In conclusion, nucleos(t)ide analogues can target initial plus-strand DNA repair and reduce but not completely block HBV infection...
  33. pmc In vitro study of the effects of precore and lamivudine-resistant mutations on hepatitis B virus replication
    Richard A Heipertz
    Milton S Hershey Medical Center, The Penn State College of Medicine, 500 University Drive, P O Box 850, Hershey, PA 17033, USA
    J Virol 81:3068-76. 2007
    ..We concluded that the rtM204I mutation generates a polymerase that is not only resistant to lamivudine but also replicates nucleic acids to lower levels in vitro...
  34. ncbi request reprint Suppression of lamivudine-resistant B-domain mutants by adefovir dipivoxil in the woodchuck hepatitis virus model
    James R Jacob
    Gastrointestinal Unit, Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY 14850, USA
    Antiviral Res 63:115-21. 2004
    ..The results demonstrate that supplemental adefovir dipivoxil treatment is effective in suppressing replication of lamivudine-resistant B-domain mutants in the woodchuck model of hepatitis B virus infection...